SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug ...

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Arvinas, Pfizer announce initial phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combo with abemaciclib at 2024 SABC symposium: New Haven, Connecticut Thursday, Dec ...

BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.

Brenig's main focus at the moment is a preclinical-stage LRRK2 inhibitor, codenamed BT-267, that it intends to move into human safety trials and proof-of-concept studies in both LRRK2-mutated and ...

Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology ...

TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- VVC Exploration Corporation, dba VVC Resources, ("VVC”), (TSX-V:VVC and ...

Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for chronic inflammatory diseases, today announced that David J.